Latest Breaking News On - Prnewswire isoplexis - Page 1 : comparemela.com

Duomic: IsoPlexis Introduces Integrated Single-Cell Functional Multi-omic Biology Platform

Duomic: IsoPlexis Introduces Integrated Single-Cell Functional Multi-omic Biology Platform
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Jon chenSean mackayRui zhengPatrick paczkowskiPrnewswire isoplexisPrecision healthGenome biologyScientist magazineRed dot

Duomic: IsoPlexis Introduces Integrated Single-Cell Functional Multi-omic Biology Platform

Jon chenSean mackayRui zhengPatrick paczkowskiPrnewswire isoplexisPrecision healthGenome biologyScientist magazineRed dot

IsoPlexis acquires extensive DNA and RNA sequencing portfolio to enable integrated single-cell sequencing and proteomic solutions

/PRNewswire/ IsoPlexis, the leader in functional single-cell proteomics, today announced the acquisition of an extensive intellectual property portfolio of.

United statesJon chenSean mackayPrnewswire isoplexisScientist magazineRed dotHealth care amp hospitalsMedical pharmaceuticalsErgers and takeoversPatent lawஒன்றுபட்டது மாநிலங்களில்ஜான் சென்சீன் மகேவிஞ்ஞானி பத்திரிகைசிவப்பு புள்ளிஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள்

IsoPlexis Partners with Bucher Biotec to Expand into Switzerland Market

Published: May 18, 2021 IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe. BRANFORD, Conn., May 18, 2021 /PRNewswire/ IsoPlexis, the leader in single-cell proteomics, today announced an exclusive agreement with Bucher Biotec AG, a Swiss distributor company representing some of the most advanced US, European, and Asian manufacturers of highly innovative life science research instrumentation, associated reagents, and consumables. This agreement follows IsoPlexis recent global distributor announcements, throughout Asia and Europe. IsoPlexis IsoLight platform has received numerous awards, recognized as both The Scientist s and Fierce Life Science s #1 innovation for the ability to provide single-cell sensitivity with highly multiplexed and quantitative functional ELISA detection together for the first time. IsoPlexis IsoLight was awarded the

South koreaJon chenPeter sieselBucher biotecIsoplexi isolightPrnewswire isoplexisPlexi isolightFierce life scienceRed dot design awardRed dot design awardsHigh design qualityChief commercialScientist magazineRed dotSoplexis partners with bucher biotec to expand into switzerland marketதெற்கு கொரியா

IsoPlexis Appoints Siddhartha Kadia to its Board of Directors

IsoPlexis Appoints Siddhartha Kadia to its Board of Directors News provided by Share this article Share this article BRANFORD, Conn., May 11, 2021 /PRNewswire/ IsoPlexis, the leader in functional single-cell proteomics, today announced the appointment of Siddhartha Kadia to its Board of Directors. Dr. Kadia joins IsoPlexis Board of Directors with over 20 years of experience in evolving a combination of technology, life science and healthcare industries. Dr. Siddhartha Kadia previously served as the President of the Life Sciences division at Life Technologies, where he managed $2B P&L which consisted of some of the most recognized brands in the industry. Additionally, Dr. Kadia served as the President and Chief Executive Officer of EAG Laboratories, a global leader for scientific testing and materials analysis across industries from aerospace and agriculture to medical devices and pharmaceuticals. He has been involved in numerous mergers, acquisitions and integrations as a

Jon chenSean mackayPrnewswire isoplexisJohns hopkins universityNewport corporationTechnical servicesHorizon discovery groupLife sciencesScripps research institute in la jollaSiddhartha kadiaIsoplexi boardLife technologiesChief executive officerBiomedical engineeringScripps research instituteCell manufacturing technologies